Bridgepoint confirms intention to list

As reported, the IPO could value the GP at £2bn.

The GP said in a statement that it expects to be eligible for the FTSE UK indices and will target a free float of 25% immediately after listing.

Bridgepoint expects to generate proceeds of £300m from the IPO, via the issue of new ordinary shares.

London-headquartered Bridgepoint invests in mid-market companies in Europe, focusing on four strategies: mid-market; lower-mid-cap; early-stage growth; and credit. The firm was founded in 2000 and had €27.4bn in assets under management as of 31 March 2021.

The GP's recent deals include the acquisition of a minority stake in fast food chain Itsu, as well as the investment in UK-based life sciences compliance and copy review business PharmaReview via its debut growth fund.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• GPs
• UK / Ireland
• IPO
• Bridgepoint